А К Голенков

889 total citations
16 papers, 451 citations indexed

About

А К Голенков is a scholar working on Hematology, Oncology and Molecular Biology. According to data from OpenAlex, А К Голенков has authored 16 papers receiving a total of 451 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 7 papers in Oncology and 6 papers in Molecular Biology. Recurrent topics in А К Голенков's work include Multiple Myeloma Research and Treatments (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Chronic Myeloid Leukemia Treatments (4 papers). А К Голенков is often cited by papers focused on Multiple Myeloma Research and Treatments (7 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Chronic Myeloid Leukemia Treatments (4 papers). А К Голенков collaborates with scholars based in Russia, United States and Germany. А К Голенков's co-authors include Н Д Хорошко, Hagop Kantarjian, Timothy P. Hughes, Andrzej Hellmann, Jerald P. Radich, Nelson Hamerschlak, Jerzy Hołowiecki, Athena Countouriotis, Tadeusz Robak and Saengsuree Jootar and has published in prestigious journals such as SHILAP Revista de lepidopterología, Blood and Anti-Cancer Drugs.

In The Last Decade

А К Голенков

14 papers receiving 434 citations

Peers

Countries citing papers authored by А К Голенков

Since Specialization

Citations

This map shows the geographic impact of А К Голенков's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by А К Голенков with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites А К Голенков more than expected).

Fields of papers citing papers by А К Голенков

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by А К Голенков. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by А К Голенков. The network helps show where А К Голенков may publish in the future.

Co-authorship network of co-authors of А К Голенков

This figure shows the co-authorship network connecting the top 25 collaborators of А К Голенков. A scholar is included among the top collaborators of А К Голенков based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with А К Голенков. А К Голенков is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

16 of 16 papers shown

#	Work	Indexed citations
1	A prospective study of the monitoring of patients with chronic myeloid leukemia upon withdrawal of tyrosine kinase inhibitor therapy 2020 ·Anna Turkina, (unknown), Ekaterina Chelysheva, (unknown), (unknown), А К Голенков, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Andrey Sudarikov, С. М. Куликов, Savchenko Vg	5
2	ASSAY OF IMMUNOGLOBULIN FREE LIGHT CHAINS IN THE SERUM FOR EVALUATING CHEMOTHERAPY EFFICACY IN PATIENTS SUFFERING FROM MULTIPLE MYELOMA WITH INTACT MEASURABLE PARAPROTEIN 2019 ·А К Голенков, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), А. В. Караулов, (unknown), (unknown)	1
3	Efficiency of lenalidomide, bortezomib and prednisone (RVP) in patients with newly diagnosed multiple myeloma 2019 ·SHILAP Revista de lepidopterología ·(unknown), (unknown), (unknown), А К Голенков, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
4	PB1911 THE CLINICAL EFFICACY OF IBRUTINIB IN RELAPSED AND RESISTANT CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS 2019 ·HemaSphere ·(unknown), А К Голенков, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	0
5	Social Parameters Are Independent Predictors for Survival in Chronic Myeloid Leukemia 2018 ·Blood ·С. М. Куликов, Anna Turkina, (unknown), (unknown), Sergey I. Kutsev, Elza Lomaia, Andrey Zaritskey, А К Голенков, (unknown), (unknown), Т. С. Константинова, Е. Н. Паровичникова, Savchenko Vg	0
6	Effect of Expression of Multidrug Resistance Genes in Newly Diagnosed Multiple Myeloma on the Clinical Course of the Disease 2016 ·Blood ·(unknown), А К Голенков, (unknown), С. С. Шушанов, (unknown)	6
7	Effect of Expression of Multidrug Resistance Genes on Efficacy the Treatment of Multiple Myeloma By Proteasome Inhibitor 2015 ·Blood ·(unknown), А К Голенков	1
8	Evaluation of Azacitidine Clinical Efficacy in Patients with Myelodysplasia Syndrome Dudina G.a., Golenkov a.K., Kataeva E.V., Mitina T.a. Moscow Regional Clinical Research Institute 2014 ·Blood ·А К Голенков	1
9	Combined phase I/II study of imexon (AOP99.0001) for treatment of relapsed or refractory multiple myeloma 2010 ·Anti-Cancer Drugs ·Thomas Moehler, Reinhard Feneberg, Anthony D. Ho, А К Голенков, Heinz Ludwig, Martin Kropff, Nuriet K. Khuageva, Jacek Hajda, (unknown), Hartmut Goldschmidt	6
10	Superior outcomes associated with complete response in newly diagnosed multiple myeloma patients treated with nonintensive therapy: analysis of the phase 3 VISTA study of bortezomib plus melphalan-prednisone versus melphalan-prednisone 2010 ·Blood ·Jean‐Luc Harousseau, Antonio Palumbo, Paul G. Richardson, Rudolf Schlag, Meletios Α. Dimopoulos, Ofer Shpilberg, Martin Kropff, Alain Kentos, Michèle Cavo, А К Голенков, Mieczysław Komarnicki, María‐Victoria Mateos, Dixie‐Lee Esseltine, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel	79
11	A235 A Prolonged Therapy Improves Quality of Response, and CR Associated with Superior Outcomes, with VMP 2009 ·Clinical Lymphoma & Myeloma ·Jean‐Luc Harousseau, Rubén Niesvizky, Antonio Palumbo, Paul G. Richardson, Rudolf Schlag, Meletios Α. Dimopoulos, Ofer Shpilberg, Martin Kropff, (unknown), Rik Schots, Michèle Cavo, А К Голенков, (unknown), MV Mateos, Andrew Cakana, (unknown), William Deraedt, Anthony Boral, Helgi van de Velde, Jesús F. San Miguel	1
12	The Alemtuzumab Treatment of Refractory to Fludarabine Chronic Lymphocytic Leukemia Patients. 2009 ·Blood ·(unknown), А К Голенков, (unknown), (unknown)	1
13	Superior Outcomes Associated with Complete Response: Analysis of the Phase III VISTA Study of Bortezomib Plus Melphalan–Prednisone Versus Melphalan–Prednisone 2008 ·Blood ·Jean‐Luc Harousseau, Antonio Palumbo, Paul G. Richardson, Rudolf Schlag, Meletios Α. Dimopoulos, Ofer Shpilberg, Martin Kropff, Michel Delforge, Rik Schots, Michèle Cavo, А К Голенков, Mieczysław Komarnicki, María‐Victoria Mateos, Andrew Cakana, Kevin Liu, William Deraedt, Helgi van de Velde, Jesús F. San Miguel	13
14	Phase II, randomized, multicenter, comparative study of peginterferon–α–2a (40 kD) (Pegasys®)versusinterferon α-2a (Roferon®-A) in patients with treatment-naïve, chronic-phase chronic myelogenous leukemia 2007 ·Leukemia & lymphoma ·Jeffrey H. Lipton, Н Д Хорошко, А К Голенков, Abdulkadyrov Km, Krishnan Padmakumari Sivaraman Nair, Raghunadharao Digumarti, Tim H. Brümmendorf, Kisook Yoo, B. Bergström	37
15	Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial 2007 ·Blood ·Hagop Kantarjian, Ricardo Pasqüini, Nelson Hamerschlak, Philippe Rousselot, Jerzy Hołowiecki, Saengsuree Jootar, Tadeusz Robak, Н Д Хорошко, Tamás Masszi, Aleksander B. Skotnicki, Andrzej Hellmann, (unknown), А К Голенков, Jerald P. Radich, Timothy P. Hughes, Athena Countouriotis, Neil P. Shah	277
16	Human Immunoglobulin Light Chains λ Form Amyloid Fibrils and Granular Aggregates in Solution 2005 ·Biochemistry (Moscow) ·(unknown), (unknown), (unknown), А К Голенков, (unknown), М. П. Самойлович, В. Б. Климович	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact